Need professional-grade analysis? Visit stockanalysis.com
$320.10M
N/A
68
N/A
Sensorion SA (ALSEN) trades on Euronext Paris in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR0.37, down 40.68% from the previous close.
Over the past year, ALSEN has traded between a low of EUR0.16 and a high of EUR0.66. The stock has lost 20.5% over this period. It is currently 44.1% below its 52-week high.
Sensorion SA has a market capitalization of $320.10M.
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing impairment. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1/2 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.